Format

Send to

Choose Destination
Transfus Med Rev. 2008 Oct;22(4):280-90. doi: 10.1016/j.tmrv.2008.05.005.

Granulocyte colony-stimulating factor administration: adverse events.

Author information

1
Department of Internal Medicine, William Beaumont Hospital, Royal Oak, MI 48073, USA. anita.dsouza@beaumont.edu

Abstract

Recombinant human granulocyte colony-stimulating factor (G-CSF) has been in clinical use for approximately 2 decades. In healthy donors, it has been used to mobilize peripheral blood progenitor cells for hematopoietic stem cell transplantation and granulocytes for apheresis collection. In patients, it has been used to decrease the duration of neutropenia after chemotherapy and to offset the neutropenia due to myelodysplasia, acquired immunodeficiency syndrome, and genetic disorders of granulocyte production. As the number of uses of G-CSF in clinical practice grows, more side effects of this generally safe pharmaceutical agent are being recognized. Our objective in this article is to provide an in-depth review of the reported adverse events associated with the use of G-CSF.

PMID:
18848155
DOI:
10.1016/j.tmrv.2008.05.005
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center